U.S. markets closed

DiaSorin S.p.A. (DIA.MI)

Milan - Milan Delayed Price. Currency in EUR
97.06-1.38 (-1.40%)
At close: 05:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close98.44
Bid97.00 x 0
Ask97.74 x 0
Day's Range96.66 - 97.80
52 Week Range94.28 - 150.30
Avg. Volume142,279
Market Cap5.245B
Beta (5Y Monthly)0.15
PE Ratio (TTM)19.77
EPS (TTM)4.91
Earnings DateMay 09, 2023
Forward Dividend & Yield1.10 (1.12%)
Ex-Dividend DateMay 22, 2023
1y Target Est113.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DIA.MI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

      Sale of assets related to Flow Cytometry & Imaging (FCI) Business UnitAcquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customersTransaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisitionEmployees associated with commercial, operations, R&D and supporting functions expected to join Cytek SALUGGIA, Italy and FREMONT, Calif., Feb.

    • PR Newswire

      BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting

      BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naïve MSCs," at the International Society of Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, CA. The poster will be presented by Dr. Kim Thacker, Senior Vice

    • PR Newswire

      BrainStorm Announces Upcoming Scientific Conference Presentations

      BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022. New data on the company's proprietary MSC-NTF exosome technology will be presented at ISCT 2022 (May 4 to 7 in San Francisco, CA) and at the ISEV 2022 Annual Meeting (May 25 to 29 in Lyon, France). An analysis of CSF biomarkers from the NurOwn® Phase 3 trial will be presented at the ALS Drug Devel